Literature DB >> 18635669

Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger.

Jun-Jie Yin1, Fang Lao, Jie Meng, Peter P Fu, Yuliang Zhao, Gengmei Xing, Xueyun Gao, Baoyun Sun, Paul C Wang, Chunying Chen, Xing-Jie Liang.   

Abstract

Intraperitoneal injection of [Gd@C82(OH)22]n nanoparticles decreased activities of enzymes associated with the metabolism of reactive oxygen species (ROS) in the tumor-bearing mice. Several physiologically relevant ROS were directly scavenged by nanoparticles, and lipid peroxidation was inhibited in this study. [Gd@C82(OH)22]n nanoparticles significantly reduced the electron spin resonance (ESR) signal of the stable 2,2-diphenyl-1-picryhydrazyl radical measured by ESR spectroscopy. Like-wise, studies using ESR with spin-trapping demonstrated efficient scavenging of superoxide radical anion, hydroxyl radical, and singlet oxygen (1O2) by [Gd@C82(OH)22]n nanoparticles. In vitro studies using liposomes prepared from bovine liver phosphatidylcholine revealed that nanoparticles also had a strong inhibitory effect on lipid peroxidation. Consistent with their ability to scavenge ROS and inhibit lipid peroxidation, we determined that [Gd@C82(OH)22]n nanoparticles also protected cells subjected in vitro to oxidative stress. Studies using human lung adenocarcinoma cells or rat brain capillary endothelial cells demonstrated that [Gd@C82(OH)22]n nanoparticles reduced H2O2-induced ROS formation and mitochondrial damage. [Gd@C82(OH)22]n nanoparticles efficiently inhibited the growth of malignant tumors in vivo. In summary, the results obtained in this study reveal antitumor activities of [Gd@C82(OH)22]n nanoparticles in vitro and in vivo. Because ROS are known to be implicated in the etiology of a wide range of human diseases, including cancer, the present findings demonstrate that the potent inhibition of [Gd@C82(OH)22]n nanoparticles on tumor growth likely relates with typical capacity of scavenging reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635669     DOI: 10.1124/mol.108.048348

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  28 in total

Review 1.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

Review 2.  Diverse Applications of Nanomedicine.

Authors:  Beatriz Pelaz; Christoph Alexiou; Ramon A Alvarez-Puebla; Frauke Alves; Anne M Andrews; Sumaira Ashraf; Lajos P Balogh; Laura Ballerini; Alessandra Bestetti; Cornelia Brendel; Susanna Bosi; Monica Carril; Warren C W Chan; Chunying Chen; Xiaodong Chen; Xiaoyuan Chen; Zhen Cheng; Daxiang Cui; Jianzhong Du; Christian Dullin; Alberto Escudero; Neus Feliu; Mingyuan Gao; Michael George; Yury Gogotsi; Arnold Grünweller; Zhongwei Gu; Naomi J Halas; Norbert Hampp; Roland K Hartmann; Mark C Hersam; Patrick Hunziker; Ji Jian; Xingyu Jiang; Philipp Jungebluth; Pranav Kadhiresan; Kazunori Kataoka; Ali Khademhosseini; Jindřich Kopeček; Nicholas A Kotov; Harald F Krug; Dong Soo Lee; Claus-Michael Lehr; Kam W Leong; Xing-Jie Liang; Mei Ling Lim; Luis M Liz-Marzán; Xiaowei Ma; Paolo Macchiarini; Huan Meng; Helmuth Möhwald; Paul Mulvaney; Andre E Nel; Shuming Nie; Peter Nordlander; Teruo Okano; Jose Oliveira; Tai Hyun Park; Reginald M Penner; Maurizio Prato; Victor Puntes; Vincent M Rotello; Amila Samarakoon; Raymond E Schaak; Youqing Shen; Sebastian Sjöqvist; Andre G Skirtach; Mahmoud G Soliman; Molly M Stevens; Hsing-Wen Sung; Ben Zhong Tang; Rainer Tietze; Buddhisha N Udugama; J Scott VanEpps; Tanja Weil; Paul S Weiss; Itamar Willner; Yuzhou Wu; Lily Yang; Zhao Yue; Qian Zhang; Qiang Zhang; Xian-En Zhang; Yuliang Zhao; Xin Zhou; Wolfgang J Parak
Journal:  ACS Nano       Date:  2017-03-14       Impact factor: 15.881

3.  Using water-soluble C60 fullerenes in anticancer therapy.

Authors:  S V Prylutska; A P Burlaka; P P Klymenko; I I Grynyuk; Yu I Prylutskyy; Ch Schütze; U Ritter
Journal:  Cancer Nanotechnol       Date:  2011-08-19

4.  [Gd@C(82)(OH)(22)](n) nanoparticles inhibit the migration and adhesion of glioblastoma cells.

Authors:  Jing Wang; Feng Gu; Ting Ding; Xiaoli Liu; Gengmei Xing; Yuliang Zhao; Ning Zhang; Yongjie Ma
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

5.  Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.

Authors:  Xing-Jie Liang; Huan Meng; Yingze Wang; Haiyong He; Jie Meng; Juan Lu; Paul C Wang; Yuliang Zhao; Xueyun Gao; Baoyun Sun; Chunying Chen; Genmei Xing; Dingwu Shen; Michael M Gottesman; Yan Wu; Jun-Jie Yin; Lee Jia
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

6.  Biomedical activities of endohedral metallofullerene optimized for nanopharmaceutics.

Authors:  Jie Meng; Dong-liang Wang; Paul C Wang; Lee Jia; Chunying Chen; Xing-Jie Liang
Journal:  J Nanosci Nanotechnol       Date:  2010-12

7.  Phototoxicity of nano titanium dioxides in HaCaT keratinocytes--generation of reactive oxygen species and cell damage.

Authors:  Jun-Jie Yin; Jun Liu; Marilyn Ehrenshaft; Joan E Roberts; Peter P Fu; Ronald P Mason; Baozhong Zhao
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-13       Impact factor: 4.219

8.  Antineoplastic activities of MT81 and its structural analogue in Ehrlich ascites carcinoma-bearing Swiss Albino mice.

Authors:  Sujata Maiti Choudhury; Malaya Gupta; Upal Kanti Majumder
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

Review 9.  Biological characterizations of [Gd@C82(OH)22]n nanoparticles as fullerene derivatives for cancer therapy.

Authors:  Jie Meng; Xingjie Liang; Xiaoyuan Chen; Yuliang Zhao
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

10.  Binding fullerenol C(60)(OH)(24) to dsDNA.

Authors:  Mariana Pinteala; Andrei Dascalu; Cezar Ungurenasu
Journal:  Int J Nanomedicine       Date:  2009-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.